Pandia Health: Clinical Gaps, Limitations, and What to Know Before You Sign Up

What Pandia Health Actually Is, and What It Is Not

Pandia Health is a cash-pay and insurance-accepting telehealth company founded in 2016 and staffed by licensed physicians, NPs, and PAs. Its core product is an asynchronous online visit that results in a prescription for hormonal contraception, delivered by mail. The platform expanded to include some menopause hormone therapy, but birth control remains its commercial center of gravity.

The company positions itself as women-first, and for a narrow use case, that claim holds up. Getting a refill of a pill you have tolerated for years, or starting a low-risk combined oral contraceptive (COC) for the first time, can work well through this kind of service. The friction of scheduling, commuting, and waiting is real, and Pandia removes it.

Where the framing breaks down is scope. Women's hormonal health does not stop at contraception. ACOG Practice Bulletin 110 documents multiple noncontraceptive indications for hormonal medications, including dysmenorrhea, endometriosis, and acne, conditions Pandia does not manage comprehensively. A woman with PCOS, postpartum thyroiditis, perimenopausal mood disruption, or hormonal acne that has stopped responding to her current pill needs more than a refill pipeline.

The Asynchronous Model: Convenience With a Clinical Cost

Most Pandia visits are asynchronous. You fill out a questionnaire; a clinician reviews it and issues or declines a prescription. There is no real-time conversation, no pelvic exam referral workflow, and no structured follow-up unless you re-initiate contact.

A 2022 analysis in JAMA Network Open found that asynchronous telehealth performs adequately for straightforward contraceptive refills but shows gaps in identifying comorbid conditions and adjusting treatment when patients report symptom changes in free-text fields that are easy to overlook or standardize away. The clinical risk is not in what the platform does, but in what it does not prompt.

Is Pandia Health Legitimate?

Yes. Pandia Health prescribers hold valid state licenses, the pharmacy is licensed, and prescriptions are real. The legitimacy question women usually mean to ask is whether the clinical standard of care is adequate for their specific situation. The honest answer is: it depends on what you need.

Clinical Gaps You Need to Know About

Pandia Health's model creates several gaps that matter for real women's health decisions. These are not marketing criticism. They are structural features of the asynchronous contraception-delivery model.

Gap 1: Menopause Care Is Shallow

Pandia offers some menopausal hormone therapy, but the formulary is narrow. As of this review, the platform prescribes standard oral estrogen-progestogen combinations and select patches. It does not prescribe:

• Vaginal estrogen for genitourinary syndrome of menopause (GSM), a condition affecting up to 45% of postmenopausal women per The Menopause Society.
• Testosterone for hypoactive sexual desire disorder (HSDD), even though The Menopause Society recommends transdermal testosterone as first-line therapy for HSDD in postmenopausal women.
• Compounded bioidentical hormones, which some perimenopausal women seek, though ACOG cautions that compounded hormones lack FDA oversight and their safety profiles are not established.
• Progesterone-only micronized formulations for women who cannot tolerate synthetic progestogens.

For a perimenopausal woman in her late 40s experiencing vasomotor symptoms, mood changes, and GSM simultaneously, a platform that can only address one or two of those symptoms is not comprehensive menopause care. The Menopause Society's 2023 position statement describes menopause hormone therapy as a multi-component decision requiring individualized assessment of symptom burden, cardiovascular risk, bone density, and breast cancer history. An asynchronous questionnaire cannot do that reliably.

Gap 2: PCOS and Fertility Are Outside Scope

Pandia does not manage PCOS, prescribe ovulation induction agents, or support women trying to conceive. This matters because PCOS affects approximately 8 to 13% of women of reproductive age according to WHO, making it one of the most common endocrine conditions a woman in her 20s or 30s will encounter.

A woman with PCOS may appropriately use a COC for cycle regulation and androgen suppression, but she also needs metabolic monitoring, discussion of insulin sensitizers such as metformin, and fertility counseling if she wants to conceive. None of that is in Pandia's clinical scope. Prescribing the pill without the broader PCOS workup is not wrong, but it is incomplete, and a woman should know that before she signs up expecting full PCOS management.

Gap 3: No Mental Health Integration

Hormonal contraception and mood are linked in ways that clinical practice has been slow to formalize. A 2023 cohort study published in PLOS Medicine of more than 260,000 women found a statistically significant association between initiating combined oral contraceptives and antidepressant prescriptions in the subsequent 12 months, with the association strongest in adolescents. Any platform prescribing COCs at scale without a mental health intake or referral pathway is operating with a real-world gap. Pandia does not include a validated mood screen in its standard intake.

Gap 4: No Lab Ordering Capability

Pandia cannot order blood work as part of a visit. For most straightforward contraception refills, that is fine. But for a woman starting hormone therapy for menopause, or one with a history suggesting thyroid disease or elevated cardiovascular risk, a clinical encounter without the option to check TSH, lipids, or glucose is structurally limited. ACOG Committee Opinion 785 recommends lipid screening in women initiating estrogen-containing contraceptives who have cardiovascular risk factors. Pandia's intake asks about risk factors but cannot verify them biochemically.

Pregnancy, Lactation, and Contraception Safety

Hormonal contraceptives are contraindicated in confirmed pregnancy. Pandia's intake questionnaire requires patients to confirm they are not pregnant, but no platform offering asynchronous care can verify this clinically. If there is any possibility you are pregnant, take a home pregnancy test before starting or restarting hormonal contraception, and follow up with an in-person clinician.

Combined Oral Contraceptives

COCs contain synthetic estrogen (typically ethinyl estradiol) and a progestogen. FDA prescribing information for combined oral contraceptives classifies them as contraindicated in pregnancy. The estrogen component may cause feminization of a male fetus and has been associated with rare congenital limb reduction defects in older literature, though more recent data is reassuring for inadvertent first-trimester exposure. The key rule: stop the pill as soon as pregnancy is confirmed.

Progestogen-Only Pills (the Mini-Pill)

Progestogen-only pills, including norethindrone (which Pandia prescribes), are sometimes considered during lactation because they do not suppress milk supply in the way combined pills may. ACOG Practice Bulletin 206 states that progestogen-only methods are generally compatible with breastfeeding. Small amounts of progestogen do transfer into breast milk, but no adverse infant developmental effects have been demonstrated at contraceptive doses.

Postpartum Timing

For women who have just delivered, the timing of contraception initiation matters. Estrogen-containing methods carry a significantly elevated venous thromboembolism (VTE) risk in the first 21 days postpartum, and ACOG recommends waiting at least 42 days before initiating estrogen-containing contraceptives in most women, and longer in those breastfeeding or with cardiovascular risk factors. Pandia's intake asks about recent delivery, but the clinical nuance of postpartum VTE risk stratification benefits from a real conversation with a clinician who knows your full history.

Menopause Hormone Therapy and Breast Cancer History

For women who have had estrogen receptor-positive breast cancer, systemic hormone therapy is generally contraindicated. ACOG and the American Society of Clinical Oncology both caution against systemic estrogen in this population. An asynchronous intake may capture this history, but the risk-benefit conversation for a breast cancer survivor considering menopause symptom treatment requires individualized oncology and gynecology input that a questionnaire cannot substitute for.

Who Pandia Health Is Right For (and Who It Is Not)

A Good Fit: Reproductive Years, Established Contraception

Pandia works well if you are in your 20s or 30s, you have already been on a specific pill formulation without problems, and you need a refill with prescription delivery. It also works for someone starting hormonal contraception for the first time with no significant medical history and no complicating conditions.

Women who fit this profile spend a lot of time waiting in primary care offices for a three-minute interaction that results in a prescription pad signature. Pandia cuts that down, and for this group, the clinical risk is low.

A Poor Fit: Complex Hormonal Conditions

Pandia is not the right platform if you:

• Have PCOS, endometriosis, or fibroids and need condition management, not just contraception.
• Are perimenopausal with multiple symptoms including mood changes, sleep disruption, GSM, and vasomotor symptoms.
• Have a history of VTE, migraine with aura, or cardiovascular disease, all of which ACOG classifies as category 3 or 4 conditions requiring careful risk-benefit analysis before prescribing estrogen-containing contraceptives.
• Are postpartum and breastfeeding and need nuanced timing guidance.
• Have female pattern hair loss, hormonal acne that has not responded to your current pill, or signs of androgen excess requiring lab evaluation.
• Are in the transition from perimenopause to postmenopause and need comprehensive hormone management rather than a single-agent prescription.

Trying to Conceive

If you are stopping contraception to try to conceive, Pandia has no services to support that transition. Fertility awareness, ovulation tracking guidance, preconception supplementation counseling, and referral to reproductive endocrinology are outside scope. You will need another provider.

How Much Does Pandia Health Cost?

Pandia accepts many insurance plans for the prescription itself. The consultation fee is separate and is generally in the range of $25 to $35 for a new patient or annual visit, though pricing has shifted over time and varies by state.

The drug cost depends entirely on your insurance formulary. Generic combined oral contraceptives under the ACA's preventive services mandate must be covered without cost sharing by most plans, though grandfathered plans and certain employer self-insured plans may be exempt. If you are uninsured, generic COCs can be purchased for $9 to $50 per month at major pharmacies, so the value proposition of Pandia's delivery model depends on how much you weight convenience over cost.

For menopause hormone therapy, insurance coverage is more variable. Branded estrogen patches and oral estradiol are often covered, but the formulary gaps described above mean that even a covered Pandia prescription may not be the right clinical choice for your symptom picture.

Pandia Health vs. Alternatives

The telehealth contraception and menopause space includes several platforms with overlapping but distinct clinical scopes. Here is a direct comparison framed around what matters clinically for women.

| Platform | Contraception | Menopause | PCOS | Lab Orders | Live Video | |---|---|---|---|---|---| | Pandia Health | Yes (COC, POP, patch, ring) | Limited (oral, patch) | No | No | No (base tier) | | Nurx | Yes (COC, POP, patch, ring, emergency) | Limited | No | Yes (STI) | No | | Wisp | Yes | Limited | No | Some | No | | Maven Clinic | Yes | Yes | Limited | Via partner | Yes | | Midi Health | Limited | Comprehensive | No | Yes | Yes | | Allara Health | Limited | Limited | Yes (primary focus) | Yes | Yes |

Midi Health and Allara Health are the strongest alternatives for women with menopause-dominant or PCOS-dominant needs, respectively. Maven Clinic offers broader scope including fertility support and mental health integration. Nurx is the closest competitor to Pandia's contraception-first model and adds STI testing kits.

No single telehealth platform currently covers the full spectrum of women's hormonal health from reproductive years through postmenopause. That gap is a structural problem in digital women's health, not a critique unique to Pandia.

The Evidence Gap: Women in Telehealth Research

Women have been historically underrepresented in clinical trials, and telehealth efficacy research is no different. Most studies of asynchronous contraceptive prescribing are small, short-term, and conducted in young, healthy, uninsured or underinsured populations who stand to benefit most from access expansion. A 2021 systematic review in Contraception covering telehealth contraception found that patient satisfaction is high and continuation rates are comparable to in-person prescribing, but safety outcomes in women with comorbidities were not well studied. That means the reassurance we have about platforms like Pandia is mostly limited to the low-risk population they serve best.

For perimenopausal and postmenopausal women specifically, no published trial has compared asynchronous telehealth hormone therapy prescribing to standard in-person gynecology or menopause specialist care. Extrapolating the contraception telehealth data to menopause management is not supported by direct evidence. The honest position is that we do not yet know whether asynchronous HRT prescribing produces equivalent outcomes to specialist care for women with complex symptom profiles.

"The asynchronous model works when the clinical question is simple and the patient population is low-risk," says Elena Vasquez, MD, a board-certified OB-GYN and WomanRx editorial board reviewer. "For a 28-year-old who tolerated the same pill for three years and needs a refill, that is appropriate. For a 51-year-old with hot flashes, brain fog, sleep disruption, and a first-degree relative with breast cancer, a questionnaire is not a substitute for a clinical conversation."

What Pandia Does Well

Criticism of clinical gaps should not obscure what the platform does accomplish. Access is a real barrier. A 2020 study in Contraception found that one in three women seeking contraception in the US reported difficulty accessing a provider, with cost, distance, and appointment availability as the leading barriers. Pandia removes those barriers for women who fit its clinical scope.

Mail delivery of contraception also reduces gaps in pill-taking. Prescription abandonment at pharmacy pickup is a documented contributor to unintended pregnancy, and a model that ships directly to your door addresses a real behavioral and logistical problem. CDC data documents that nearly half of all pregnancies in the US are unintended, and contraceptive access gaps are a contributing factor.

For women in states where reproductive healthcare access has been restricted following the Dobbs decision, telehealth contraception platforms have expanded in clinical and legal importance. Pandia operates in this environment and provides services in most states, which is clinically meaningful for women who have lost in-person options.

How Sex-Specific Physiology Affects What Pandia Prescribes

Oral contraceptive pharmacokinetics differ by body weight, and this has clinical implications. A pharmacokinetic study published in Contraception showed that ethinyl estradiol area under the curve (AUC) is significantly lower in women with higher body weight, raising theoretical concerns about efficacy. The FDA has not set a weight cutoff for COC use, and ACOG Practice Bulletin 110 does not recommend against COC use based on BMI alone, but this nuance does not appear in a standard online intake. A clinician who knows you can discuss whether a progestogen-only pill or a long-acting reversible contraceptive (LARC) might be a stronger choice.

Smoking status matters enormously. Estrogen-containing contraceptives in women over 35 who smoke carry a meaningfully elevated VTE and arterial thrombosis risk. ACOG classifies this combination as a WHO Medical Eligibility Criteria Category 4, meaning contraindicated. Pandia's intake asks about smoking, and the algorithm should flag this, but the absence of a real-time clinician means nuanced conversations about partial smoking cessation or e-cigarette use may not be handled with adequate clinical depth.

Migraine with aura is another category 4 contraindication for estrogen-containing methods. Women sometimes underreport aura or do not recognize it as distinct from migraine without aura. A clinician who asks follow-up questions catches this; a standardized form may not.